트라스투주맙 엠탄신
|
|
트라스투주맙 엠탄신 속성
- 저장 조건
- Store at -20°C
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
| 그림문자(GHS): |
  
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 신호 어: | Danger | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 유해·위험 문구: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 예방조치문구: |
|
트라스투주맙 엠탄신 C화학적 특성, 용도, 생산
개요
T-DM1 is a human epidermal growth factor receptor (HER2)-targeted antibody drug conjugate (ADC) that was approved in February 2013 by the US FDA for use as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer (mBC) who previously received treatment with trastuzumab and a taxane, separately, or in combination. T-DM1 is composed of trastuzumab linked to the potent cytotoxic microtubule polymerization inhibitor DM1 (derivative of maytansine) via a stable uncleavable thioether linker. T-DM1 is produced by chemically crosslinking the cytotoxic maytansinoid derivative to the lysine residues of trastuzumab such that there is an average of 3.5 cytotoxic molecules linked to each antibody. In addition to delivering DM1 to tumor cells, T-DM1 retains the effector functions of trastuzumab, including inhibition of HER2-mediated signal transduction and activation of antibodydependent cell-mediated cytotoxicity.Originator
Genentech, a member of the Roche Group (United States)상표명
Kadcyla트라스투주맙 엠탄신 준비 용품 및 원자재
원자재
준비 용품
트라스투주맙 엠탄신 공급 업체
글로벌( 30)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21691 | 55 |
| BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19553 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 15093356674; |
laboratory@coreychem.com | China | 30255 | 58 |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 |
masar@topule.com | China | 8474 | 58 |
| LEAPCHEM CO., LTD. | +86-852-30606658 |
market18@leapchem.com | China | 43348 | 58 |
| Shanghai jerryxing Biomedical Technology Co., Ltd | 17721492509 |
643638326@qq.com | China | 5347 | 58 |
| Chembest Research Laboratories Limited | 021-20908456 |
sales@BioChemBest.com | China | 6011 | 61 |
| Wuhan Sunrise Technology Development Co., Ltd. | 027-027-83314682 13554138826 |
whsrtech@vip.163.com | China | 300 | 62 |
| EnliPharma Technology Co., Ltd | 0551-66399836 18955197623 |
sales@enlipharma.com | China | 1874 | 55 |
| Nanjing Vital Chemical Co., Ltd. | 025-87193546 18652950785 |
chemweiao@163.com | China | 9030 | 60 |
트라스투주맙 엠탄신 관련 검색:
Follicle stimulating hormone
Secukinumab
Daratumumab
OMALIZUMAB
Dulaglutide
Ranibizumab
palivizumab
Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
Eculizumab
Matuzumab
ticilimumab tremelimumab
CNTO 148
Aflibercept
abciximab
Vedolizumab
Avelumab
nimotuzumab
belimumab